New hope for High-Risk leukemia: testing a gentler bridge to cure
NCT ID NCT07425782
Summary
This study is for adults with a high-risk type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares two different treatments given before the transplant to help keep the cancer from coming back. One treatment uses a newer drug combination (venetoclax + azacitidine), while the other uses a standard chemotherapy. The goal is to see which approach is more effective and safer at preventing relapse and improving long-term survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.